Minimally invasive diagnostic procedures such as needle-core biopsy and fine-needle aspiration provide adequate material for molecular analyses. Advances in precision oncology are trending toward the interrogation of limited amounts of genomic material to guide clinical and therapeutic decisions. The aim of this study was to investigate the minimum cellularity needed on cytologic smears for the identification of clinically relevant variants with next-generation sequencing (NGS). METHODS: Thirty cases of cytologically diagnosed, resection-proven primary lung adenocarcinoma were identified. Nineteen of the 30 cases were known to harbor actionable variants. One Diff-Quik (DQ)-stained slide and 1 Papanicolaou (Pap)-stained slide were selected from each case. Cases were categorized as containing fewer than 100 tumor cells, 100 to 500 tumor cells, or more than 500 tumor cells. NGS was performed on the Ion Torrent platform.
INTRODUCTION
Advances in the understanding of molecular drivers of non-small cell lung cancer have led to the emergence of 3 generations of tyrosine kinase inhibitors that target tumors with genomic alterations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK) fusion genes. [1] [2] [3] [4] [5] [6] The updated 2016 draft of the Molecular Testing Guidelines for Selection of Lung Cancer Patients, developed by the College of American Pathologists, the Association for Molecular Pathology, and the International Association for the Study of Lung Cancer, strongly recommends molecular testing of the EGFR and ALK genes in lung adenocarcinoma patients at the time of their diagnosis. It further recommends the use of either cell blocks (CBs) or other cytologic preparations as suitable specimens for lung cancer biomarker molecular testing. A recent review of biomarker testing in lung carcinoma cytology specimens from the Pulmonary Pathology Society stressed the importance of evaluating the adequacy of cytologic specimens for determining utility as a diagnostic indicator. 7 In addition to EGFR and ALK, testing for variants in B-Raf proto-oncogene, serine/threonine kinase (BRAF), Erb-B2 receptor tyrosine kinase 2 (ERBB2), Kirsten rat sarcoma (KRAS), MET proto-oncogene, receptor tyrosine kinase (MET), and Ret proto-oncogene (RET) genes in lung tumors is recommended when other treatment options need to be identified. The concurrent identification of multiple single-nucleotide variants and indels in EGFR and other clinically relevant genes is easily achieved with massively parallel sequencing, or next-generation sequencing (NGS). Several laboratories have adopted targeted NGS as the platform of choice for the interrogation of clinically relevant variants in patients with lung adenocarcinoma. Despite advances in screening methods, the majority of non-small cell lung cancers are diagnosed at an advanced stage at which the tumors are surgically unresectable, and clinicians will opt for minimally invasive diagnostic procedures, such as needle-core biopsy and fine-needle aspiration (FNA) cytology. 6 Cytologic preparations often determine the extent of the ancillary testing necessary for providing a final diagnosis. Usually, the FNA specimen is processed as a formalin-fixed, paraffin-embedded (FFPE) CB and direct smears (DSs). The latter include air-dried Diff-Quik (DQ)-stained DSs and alcohol-fixed Papanicolaou (Pap)-stained DSs. In situations where the CB either shows scant cellularity or has been exhausted for diagnostic immunohistochemistry, pathologists may be left with only a DQ-or Pap-stained DS for molecular testing. FNA smears also may be amenable to molecular testing because of the minimal processing, which saves time and safeguards the DNA from the harshness of FFPE fixation. However, the success of FNA smears as specimens for NGS has limitations that are directly related to the adequacy of the specimens. Studies that have investigated the use of NGS on FNA smears from lung adenocarcinomas are limited and often lack direct comparators for an assessment of results and a determination of statistical significance. [8] [9] [10] [11] [12] [13] In our comprehensive study, we have used FNA CBs and corresponding DQ and Pap smears from 30 cytologic specimens to ascertain the adequacy of FNA smears as a specimen type for NGS.
MATERIALS AND METHODS
This study was approved by the institutional review board of the NewYork-Presbyterian Hospital/Weill Cornell Medicine in New York, NY.
Histologically proven primary pulmonary adenocarcinomas, diagnosed between October 2013 and June 2015 with molecular studies performed on FNA CBs, were identified for the study by a computerized search. A molecular analysis of each CB was performed during the initial routine clinical workup of the cases at the request of the treating physicians. Twenty-seven of the cases had molecular information on the resected tumor. In all, 30 cases for which the CB was sequenced-19 cases harboring clinically relevant variants, 1 indeterminate case, and 10 wildtype tumors-were selected for the study. All 30 specimens had both DQ and Pap DSs available for analysis.
Specimen Collection
Tumors were targeted by interventional radiology with either computed tomography-guided or endobronchial ultrasound-guided FNA. The cytologist prepared 2 DSs during the first FNA pass: one was air-dried and stained with DQ, and the other was immediately fixed in 95% ethanol for later Pap staining. If the specimen was deemed adequate and diagnostic with DQ staining, the residual material was rinsed in CytoLyt (Hologic, Inc, Bedford, Mass) for CB processing and was fixed in formalin and embedded in paraffin (FFPE).
Molecular Analysis of CB and DS Specimens
In the Molecular Pathology Laboratory at NewYorkPresbyterian Hospital/Weill Cornell Medicine, Sanger sequencing for targeted genes (EGFR and KRAS) was used for molecular analysis before 2015, after which NGS became the primary modality for the molecular testing of lung tumors.
For sequencing, 5-mm sections for 10 unstained slides and 1 section stained with hematoxylin and eosin were cut from the FNA CB. The tumor-enriched area was circled on the hematoxylin and eosin stain by a cytopathologist, and the neoplastic cellularity was estimated as the relative amount of tumor cells versus nonneoplastic nucleated cells. One DQ-stained slide and 1 Pap-stained slide from each case were selected for NGS. Whole-slide imaging was performed for digital archiving before DNA extraction (Aperio/Leica Microsystems, Buffalo Grove, Ill). The scanned slide images of the cases were viewed in their entirety and categorized as containing fewer than 100 tumor cells, 100 to 500 tumor cells, or more than 500 tumor cells. Most of the cases with fewer than 100 cells and more than 500 cells were obvious, and for borderline cases, tumor cells on the computer screen, moving in a systematic manner (up and down from left to right), were counted. The tumor percentage was estimated as the relative amount of tumor cells versus nonneoplastic nucleated cells. Necrotic material, red blood cells, and acellular debris were not taken into consideration for overall cellularity. We estimated the tumor percentage on smears by first reviewing the entire slide and then selecting 3 representative areas of cells for the assessment of tumor cellularity to the nearest 10% on average for the groups of cells.
All slides were reviewed by the same pathologist to eliminate potential interobserver variability. The coverslips were removed via the soaking of the samples in xylene until the coverslip either detached on its own or was easily detached manually (24-96 hours). All of the material was scraped from the surface of the slides with straight-blade razors into 1.5-mL microcentrifuge tubes. One razor was used per slide to prevent DNA cross-contamination. DNA was isolated with a QIAamp DNA kit (Qiagen, Inc, Valencia, Calif). NGS and data analyses were then performed as described previously. DNA was quantified with both a Qubit 2.0 fluorometer (Thermo Fisher Scientific) and a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). 
Statistical Analysis
The 1-way analysis-of-variance method was used for 3-way comparisons. Paired 2-tailed t tests were used to compare DQ and Pap smear molecular characteristics from each case. P < .05 was considered statistically significant.
RESULTS

Patient Characteristics
The male/female ratio was 8:7, and the mean age was 70.2 years (median, 71 years; range, 55-85 years). The tumors at resection were graded as well (n 5 6), moderately (n 5 14), or poorly differentiated (n 5 10). The tumors were staged at resection according to the 7th edition of the American Joint Committee on Cancer lung cancer staging system. 14 Seventeen tumors were stage IA, 5 were stage IB, 2 were stage IIA, 1 was stage IIB, 4 were stage IIIA, and 1 was stage IV. Twenty-nine of the 30 cases were classified as adenocarcinoma at resection, and 1 case was classified as adenosquamous carcinoma. Molecular data from Sanger sequencing or NGS of 27 of the 30 resected tumors were also used for comparison.
Cytology FNA Smear Characteristics
Paired DQ and Pap smears from each case showed similar cellularity, and cases that differed in cellularity were within 1 category of each other and, therefore, not significantly different. Two DQ smears showed fewer than 100 cells, 18 showed 100 to 500 tumor cells, and 10 showed more than 500 tumor cells. The mean tumor percentage identified on the DQ smears was 46% (range, 10%-80%). Four Pap smears showed fewer than 100 tumor cells, 15 showed 100 to 500 tumor cells, and 11 showed more than 500 tumor cells. The mean tumor percentage for Pap smears was 47% (range, 10%-80%). Table 1 shows details of the correlation between the tumor cellularity on the smear and the outcome of NGS.
Presequencing Molecular Characteristics
The Qubit DNA concentration was available for 15 of the 16 CBs analyzed by NGS. The mean Qubit DNA concentration was 4.9 ng/lL. NanoDrop DNA concentrations were available for 12 of the 14 CBs analyzed by conventional Sanger sequencing. The mean DNA concentration by NanoDrop was 6.5 ng/lL. DNA library concentration information was available for 8 CBs analyzed by NGS. The mean library concentration was 986 pM. Presequencing molecular characteristics, including the Qubit DNA concentrations and library concentrations for all of the study DQ smears (n 5 30) and Pap smears (n 5 30), are shown in Table 2 . The mean Qubit DNA concentration for DQ smears was 11.1 ng/lL, and for Pap smears, the mean was lower at 5.5 ng/lL (P 5 .04). The mean library concentration for DQ smears was 502.7 pM, whereas the mean library concentration for Pap smears was significantly higher at 1275.0 pM (P 5 .01). There were 27 Pap smears and 27 DQ smears sequenced: 20 of the Pap specimens (74%) generated libraries with concentrations > 100 pM, whereas 14 of the DQ specimens (52%) did. The variant read depth and the variant allelic fraction (VAF) obtained after the sequencing of the 3 different specimen types were comparable.
Genomic Variant Profiles of Cytology Specimens
NGS was successfully performed on all 16 CBs and on 54 of 60 DSs (90%). In 3 cases, NGS failed for both DQ and Pap smears (Table 3) . One of the 3 failures was attributed to tumor cellularity of fewer than 100 cells in both DQ Abbreviations: APC, adenomatous polyposis coli; ATM, ATM serine/threonine kinase; BRAF, B-Raf proto-oncogene, serine/threonine kinase; CB, cell block; CDKN2A, cyclin-dependent kinase inhibitor 2A; CTNNB1, catenin b1; DQ, Diff-Quik; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma; MET, MET proto-oncogene, receptor tyrosine kinase; NGS, next-generation sequencing; Pap, Papanicolaou; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a; STK11, serine/threonine kinase 11; TP53, tumor protein P53. All DQ and Pap smears were analyzed with NGS. a In these cases, CBs were analyzed by Sanger sequencing for EGFR and KRAS variants. In all other cases, CBs were analyzed by NGS.
detect the KRAS G12C driver variant. The variant was, however, detected in the resected specimen, for which the tumor percentage was 30%. Variants in the cyclindependent kinase inhibitor 2A (CDKN2A) and tumor protein P53 (TP53) genes were not interrogated in the CBs (numbers 3 and 30) that underwent Sanger sequencing. Interestingly, clinically relevant variants were successfully identified in the Pap smears and CBs for 2 cases but were absent in the DQ smears. One specimen (number 22) with a confirmed exon 19 deletion of the EGFR gene had fewer than 100 tumor cells on the DQ smear alone, and the second specimen (number 16) failed to generate a quantifiable library. The NGS coverage from these specimens was suboptimal and did not meet the quality-control standards for the assay. In the corresponding resection specimen for which the tumor cellularity was >70%, the clinically relevant variants were detected. Notably, 2 of the 3 specimens for which NGS failed with both DQ and Pap smears harbored actionable EGFR variants when the CB and resections were tested. One of the failures (number 8) with an EGFR exon 19 deletion had low cellularity (fewer than 100 tumor cells) on both smear specimens. When the cellularity was between 100 and 500 tumor cells, the DNA concentration obtained from the other failed smear specimens (numbers 11 and 17) was < 1.0 ng/mL, and the NGS libraries that were generated were unsuccessful and did not have any amplifiable DNA. Overall, cases with more than 100 tumor cells had a 93% success rate (n 5 54), whereas those cases with fewer than 100 tumors cells successfully underwent NGS only 67% of the time (n 5 6). NGS success was related to tumor cellularity in the cytologic smears. See Tables 1 and 3 for details on tumor cellularity and a complete list of variants identified by case.
The mean VAF for the 20 hotspot variants identified by NGS (Table 2) There was no significant difference among the 3 comparisons. The mean depth of coverage (Table 2) for variants successfully identified by NGS on CB was 10173. The mean depth of coverage for DQ smears at 1040 3 was very slightly lower than the mean depth of coverage for Pap smears at 12583.
DISCUSSION
In the realm of precision medicine and targeted therapeutics, the ability of NGS to concurrently detect compound genomic alterations has favored its implementation in routine clinical practice. Detecting multiple targets in a single assay is of particular interest in cytopathology, where diagnostic material and additional material for ancillary testing are often limited. Because only 25% to 30% of patients with non-small cell lung cancer undergo subsequent surgical resection after the initial diagnosis, the ability to use all available FNA material for ancillary molecular testing is of the upmost importance. The 2016 draft of the Molecular Testing Guidelines for Selection of Lung Cancer Patients recommends the use of FFPE specimens and fresh, frozen, or alcohol-fixed specimens for lung cancer biomarker molecular testing. It further recommends using either CBs or other cytologic preparations as suitable specimens for lung cancer biomarker molecular testing. The molecular and cytogenetic applications of cytologic specimens have been discussed by leaders in the field and in a special section of a recognized pathology journal. 7, [15] [16] [17] [18] [19] Contributing authors have discussed their experiences with pre-analytic variables, with optimizing the workflow, and with maximizing small biopsy and cytology specimens for molecular and ancillary testing. 7, [15] [16] [17] [18] Although FFPE tissue from core biopsies and CBs prepared from FNA procedures has been established as a viable sample type for NGS in molecular pathology, 20 there is a paucity of data on the application of other cytologic preparations such as DSs (DQ and Pap) for targeted NGS assays in the clinical laboratory. The advantages and shortcomings of using liquidbased cytology specimens, including DSs, for ancillary testing have been expanded upon in a review by Saqi. 17 A limited number of studies have demonstrated the successful use of NGS on FNA smears of primary pulmonary adenocarcinoma. [8] [9] [10] [11] [12] [13] Using Targeted NGS on the Ion Torrent platform, Scarpa et al 9 showed a concordance of variants identified in 2 cases of matched tumor biopsy. In a similar study, 5 corresponding cytology specimens, including FFPE, DQ, and Pap specimens, sequenced on the Illumina platform were also determined to harbor identical variants. 8 However, the sample selection for the FFPE block did not factor in the important element of tumor cellularity. A more recent study of the utility of cytologic specimens in NGS compared the variants detected in CBs to a single smear type: either DQ or Pap. 10 22 who demonstrated that spray and ethanol fixation resulted in both a higher yield and better DNA quality than air drying. A review article from the MD Anderson group that addresses the pre-analytic variables in cytologic specimens does not, however, note any noticeable difference between DQ and Pap smears subjected to NGS. 16 The authors, however, state that the direct comparison of 3 DQ smears and 13 Pap smears may not have been optimal, and they recommend additional studies to address the effect of smear preparation and fixation on success with NGS. The current study documents our experience of a head-to-head comparison of 30 DQ and Pap smears from the same FNA specimens. Concurrent data on the matched CBs and resections (data not shown) from these tumors provide supportive evidence. Higher quality input DNA for NGS from smears may further partially explain why additional variants (TP53, KRAS, and EGFR) were identified in 2 cases with DNA extracted from the Pap smears but not the DQ smears. In 1 discordant case, the Pap smear yielded a higher library concentration than the DQ smear even on repeat analysis. In the other discordant case, the DQ smear actually showed a higher DNA yield and library concentration, and this indicated another factor, possibly contributed by tumor heterogeneity. In fact, the results obtained from the corresponding resection are supportive of potential heterogeneity for the CB and the Pap smear. It is important to note that the spectrum of variants harbored within the cytologic specimens covered single-nucleotide variants in 12 different clinically relevant genes, including actionable targets. In addition, the DNA obtained from both DQ and Pap specimens could be used to confidently identify targetable deletions up to 15-bp, insertions of 9 bp, and the important T790M resistance variant in the EGFR gene. Moreover, despite the variable amounts of extracted DNA and library yields between DQ and Pap specimens, the VAF of the genomic variants showed a reasonably good overall correlation. This attests to the analytical robustness of NGS assays performed for clinical purposes.
DSs prepared from liquid cytology specimens are not technically demanding to prepare and, therefore, are easily accessible for ancillary studies in settings where onsite cytopathologists are unavailable. Our findings highlight the importance of cytopathologists' performing a molecular adequacy assessment at the time of smear preparation for the appropriate selection of smears used for NGS. We demonstrated that NGS was successful in 93% of cases with more than 100 tumor cells on a single slide, whereas those with fewer than 100 tumor cells had only a 68% success rate. This observation is in line with previous reports showing that successful molecular analyses are dependent on tumor cellularity. The data in the study show that smears used for NGS analyses can reliably be tested up to 2 years after they are prepared. Studies to document increased stability over time would be helpful.
Cytology smears are an invaluable alternative to repeat endobronchial ultrasound when the adequacy of CBs is an issue. Smears should be used for ancillary testing primarily when additional slides are available because it may be necessary to re-evaluate diagnostic material for future reference. Digital images of the smears can potentially serve as informative archival records for cases in which the smears have to be sacrificed as the only diagnostic material. The limitations to using cytology smears, as seen in this investigation, are very low tumor cellularity (fewer than 100 cells) and likely tumor heterogeneity, which could well be more apparent in specimens with limited material for molecular analyses. In addition, the process for decoverslipping the stained smear can take anywhere from 24 to more than 48 hours and could, therefore, affect the turnaround time for obtaining an NGS result. The recent review of biomarker testing in lung carcinoma cytology specimens documented by the members of the Pulmonary Pathology Society 7 indicates the need for further rigorous validation for assays that use DSs for reporting clinically relevant variants in ancillary studies. To our knowledge, ours is the first in-depth study to demonstrate parameters that are important for the successful use of NGS with paired DQ and Pap smears in addition to FFPE CBs. This investigation clearly shows the feasibility of using cytologic smears with adequate tumor cellularity for the identification of clinically relevant variants in lung adenocarcinoma.
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